Improved Glucose Control with Weight Loss, Lower Insulin Doses, and no Increased Hypoglycemia with Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes EMPA-REG MDI Trial Investigators. The gene discussed is INS; the disease is Hypoglycemia.